Inhibrx Adopts DNASTAR Lasergene Software
DNASTAR today announced that Inhibrx has entered into an agreement supporting an organization-wide site license of DNASTAR Lasergene software. This license provides access to DNASTAR software for all employees of Inhibrx.
John Timmer Ph.D., the Research Director of Inhibrx commented, “After using Lasergene software in-
house to meet our day to day sequence analysis needs, it became clear that a long-term, company-wide site license of the software makes sense for our organization. We have found the software to be easy to use and powerful, and DNASTAR’s technical support has been very responsive and on point. By committing to this license for multiple years, our scientists can count on a consistent, strong platform being available to them throughout their research projects. We look forward to using Lasergene on an increasing basis as we continue to grow our business.”
Tom Schwei, Vice President and General Manager of DNASTAR, stated, “We appreciate the confidence shown by Inhibrx in making this multi-year commitment to using our software as an integral part of their research and business. As a leading-edge firm in developing fit-for-function biotherapeutics, Inhibrx represents a great fit for our software platform, now and into the future. We look forward to supporting the research and business of Inhibrx through ongoing development and delivery of a strong software offering."
Financial terms of the arrangement were not disclosed.